Gad Cotter Selected Research

tezosentan

1/2017	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS).
8/2005	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome.
8/2004	The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
7/2003	Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
1/2003	RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gad Cotter Research Topics

Disease

105	Heart Failure 01/2022 - 01/2003
14	Renal Insufficiency (Renal Failure) 01/2020 - 04/2009
13	Dyspnea (Shortness of Breath) 01/2019 - 07/2003
7	Inflammation (Inflammations) 01/2022 - 03/2012
6	Weight Loss (Weight Reduction) 01/2022 - 05/2013
6	Heart Diseases (Heart Disease) 11/2017 - 10/2013
5	Cardiogenic Shock 09/2021 - 06/2002
5	Atrial Fibrillation 01/2016 - 11/2003
5	Myocardial Infarction 05/2007 - 01/2003
3	Disease Progression 01/2021 - 10/2010
3	Edema (Dropsy) 01/2020 - 01/2014
3	Hypotension (Low Blood Pressure) 11/2019 - 07/2003
3	Body Weight (Weight, Body) 01/2019 - 01/2008
3	Diabetes Mellitus 10/2017 - 10/2012
3	Hypertension (High Blood Pressure) 05/2014 - 07/2004
3	Acute Coronary Syndrome 07/2003 - 09/2001
2	Shock 09/2021 - 01/2008
2	Neoplasms (Cancer) 01/2021 - 01/2021
2	Respiratory Sounds (Crackle) 02/2016 - 07/2014
2	Anemia 05/2013 - 10/2012
2	Seizures (Absence Seizure) 03/2012 - 10/2010
2	Stroke (Strokes) 03/2012 - 07/2004
2	Left Ventricular Dysfunction 01/2008 - 03/2006
2	Infarction (Infarctions) 05/2007 - 12/2003
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 05/2006 - 07/2004
2	Pulmonary Edema 08/2003 - 01/2003
1	Critical Illness (Critically Ill) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Alcoholic Fatty Liver 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Hypoglycemia (Reactive Hypoglycemia) 01/2020
1	Bone Fractures (Bone Fracture) 01/2020
1	Liver Diseases (Liver Disease) 12/2019
1	Bradycardia 11/2019
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 03/2017

Drug/Important Bio-Agent (IBA)

16	rolofyllineIBA 01/2018 - 10/2008
14	RelaxinIBA 12/2021 - 04/2009
13	DiureticsIBA 01/2022 - 01/2008
13	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
11	CreatinineIBA 01/2022 - 01/2012
11	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 08/2005
7	Purinergic P1 Receptor AntagonistsIBA 01/2018 - 01/2010
7	Urea (Carbamide)FDA LinkGeneric 01/2017 - 08/2005
5	Pharmaceutical PreparationsIBA 01/2021 - 01/2008
5	NitrogenIBA 01/2017 - 08/2005
5	tezosentanIBA 01/2017 - 01/2003
5	Adenosine (Adenocard)FDA LinkGeneric 03/2012 - 10/2008
4	Furosemide (Lasix)FDA LinkGeneric 01/2022 - 07/2003
4	Glucose (Dextrose)FDA LinkGeneric 04/2021 - 02/2008
4	Natriuretic PeptidesIBA 01/2019 - 01/2017
4	TroponinIBA 01/2017 - 11/2005
4	Adenosine A1 ReceptorIBA 11/2016 - 10/2008
4	Hemoglobins (Hemoglobin)IBA 02/2016 - 01/2008
4	Troponin T (Troponin T1)IBA 01/2016 - 11/2011
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2006 - 04/2003
3	C-Reactive ProteinIBA 01/2022 - 02/2016
3	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2022 - 11/2014
3	SodiumIBA 04/2021 - 01/2014
3	LigandsIBA 02/2018 - 03/2015
3	salicylhydroxamic acid (SHAM)IBA 11/2017 - 02/2016
3	Vasodilator Agents (Vasodilators)IBA 12/2009 - 04/2004
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2021
2	AdrenomedullinIBA 09/2021 - 01/2020
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2021 - 03/2015
2	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 11/2019
2	Endothelin-1 (Endothelin 1)IBA 12/2020 - 08/2005
2	Growth Differentiation Factor 15IBA 11/2019 - 11/2015
2	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHIBA 02/2018 - 03/2015
2	Type 1 Angiotensin ReceptorIBA 02/2018 - 08/2017
2	MicroRNAs (MicroRNA)IBA 12/2016 - 01/2016
2	NitratesIBA 10/2016 - 10/2013
2	AlbuminsIBA 01/2016 - 01/2014
2	Nitric Oxide Synthase (NO Synthase)IBA 05/2007 - 07/2003
2	Dobutamine FDA LinkGeneric 03/2006 - 11/2005
2	Endothelins (Endothelin)IBA 08/2004 - 01/2003
2	cyclopropapyrroloindoleIBA 07/2004 - 08/2003
2	Glycoproteins (Glycoprotein)IBA 04/2003 - 09/2001
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Nitroglycerin (Dynamite)FDA LinkGeneric 12/2021
1	IvabradineIBA 04/2021
1	Neprilysin (Neutral Endopeptidase)IBA 04/2021
1	Galectin 3 (LGALS3)IBA 01/2021
1	nasIBA 01/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020
1	ReninIBA 12/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2018
1	angiogeninIBA 10/2017
1	proenkephalinIBA 03/2017
1	PotassiumIBA 01/2017

Therapy/Procedure

29	Therapeutics 01/2022 - 09/2001
17	Patient Readmission 01/2020 - 02/2004
15	Length of Stay 01/2020 - 01/2010
3	Percutaneous Coronary Intervention 01/2006 - 09/2001
2	Injections 12/2020 - 09/2010
2	Intravenous Infusions 01/2019 - 01/2013
2	Electric Countershock (Cardioversion) 01/2016 - 11/2003
1	Cell- and Tissue-Based Therapy (Cell Therapy) 03/2017
1	Biological Therapy 03/2017